📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade (2019)

First Author: Vuong L

Attributed to: MRC Centre for Regenerative Medicine funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/0008-5472.can-18-2244

PubMed Identifier: 30674531

Publication URI: http://europepmc.org/abstract/MED/30674531

Type: Journal Article/Review

Parent Publication: Cancer Research

Issue: 7

ISSN: 0008-5472